

NOT FOR PUBLICATION
FOR OFFICIAL USE ONLY

POLIOMYELITIS SURVEILLANCE
REPORT NUMBER 13
MAY 14, 1955
INCLUDING A WEEKLY SUMMARY

DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE
PUBLIC HEALTH SERVICE

COMMUNICABLE DISEASE CENTER
Theodore J. Bauer, M.D., Chief

EPIDEMIOLOGY BRANCH

Alexander D. Langmuir, M.D., Chief
Ira L. Myers, M.D., Asst. to Chief

POLIOMYELITIS SURVEILLANCE UNIT
Neal Nathanson, M.D., Chief
Earl Diamond, M.A., Statistician

Address: 50 Seventh Street, N.E., Atlanta 5, Georgia

Phone Numbers:

Daytime, Monday - Friday, 8:00 AM - 5:30 PM EST: Elgin 3311
Night, 5:30 PM - 10:00 PM EST, and Sat. and Sun: Elgin 2176

Home Phones:

Dr. Neal Nathanson	CHerokee	7520
Mr. Earl Diamond	ATwood	2791
Dr. A. D. Langmuir	CRescent	9207
Dr. Ira L. Myers	DEarborn	0482

SPECIAL NOTE

The information provided in this report represents the latest data reported to the Poliomyelitis Surveillance Unit from State Health Departments, Epidemic Intelligence Service Officers, participating laboratories, and other pertinent sources. Much of the material is preliminary in nature and is subject to confirmation and change. It is distributed for the benefit of all participants with the understanding that it will not be released to the press or to unauthorized persons. Any release of this information will be strictly limited to the Office of the Surgeon General, United States Public Health Service, Washington, D.C. In such releases cases will be identified by State only; initials and residence will not be made public. State Health Officers, of course, are free to reveal any information they may wish concerning data from their State.

One new case was accepted today from Delaware (Dr. Floyd Hudson, Polio Reporting Officer). This eight-year-old male developed symptoms 24 hours after receiving Wyeth Vaccine and showed weakness of both legs when first examined by a physician 10 days later. PSU Case No. Tex-1 was revised today on receipt of further information. This 7-year-old male was inoculated in the left arm with Lilly Vaccine and developed mild bulbar signs 9 days later. There was no paralysis in the left arm as originally reported.

A total of 74 cases have been accepted through 12:00 noon today (5-14-55) and are summarized below (Table 1).

Table 1
Cases by State and Manufacturer
(PSU Accepted Cases through May 14, 1955)

State	Cutter	Lilly	Parke-Davis	Pittman-Moore	Wyeth	Total
California	24*					24
Idaho	16*					16
Oregon	3					3
Louisiana	1	2*				3
Washington	1					1
Colorado	1					1
Illinois	1					1
Indiana		1				1
Georgia	1	1				2
New York	1					1
West Virginia		2				2
Texas	1	4**				5
Hawaii	1					1
Missouri	1					1
Nevada	3					3
Pennsylvania					2	2
Wyoming	2					2
Connecticut	1*					1
Mississippi		1				1
Ohio	1					1
Virginia		1*				1
Delaware					1	1
Total	59	12	0	0	3	74

* Includes 1 non-paralytic case.

** Includes 3 non-paralytic cases.

Suspect cases are under investigation in California, Idaho, Kansas, and Nebraska.

(NEAL NATHANSON for JPH.)

NEAL NATHANSON, M.D., CHIEF
POLIOMYELITIS SURVEILLANCE UNIT

NOT-FOR PUBLICATION
FOR OFFICIAL USE ONLY

MAY 14, 1955
12:00 AM

DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE
PUBLIC HEALTH SERVICE COMMUNICABLE DISEASE CENTER

POLIOMYELITIS SURVEILLANCE UNIT
Accepted Cases Associated with Poliomyelitis Vaccine
Daily Supplementary Report

PSU CASE NO.	Residence	Init- ials	Age	Sex	Date Inoc	Date 1st Symp	Date 1st Para	Site Inoc	Site 1st Para	Mfr	Lot No	Remarks
Del-1	Wilmington	DM	8	M	4-29	4-30	?	LA	Legs	W	23610	Onset 24 hours after vaccination

REVISIONS
(Revised Items Underlined)

Tex-1	Houston	HH	7	M	4-19	4-27	4-28	LA	<u>Bulbar</u>	L	7078-649343	
WVa-2	Mabscot	TAC	6	M	4-21	5-4	5-5	LA	Legs	L	8122- <u>649334</u>	

Code of Abbreviations:

PSU - Poliomyelitis Surveillance Unit
Mfr - Manufacturer
C - Cutter Laboratories
L - Lilly Laboratories
W - Wyeth Laboratories

LA - Left Arm
RA - Right Arm
LL - Left Leg or Buttocks
RL - Right Leg or Buttocks

THIRD WEEKLY SUMMARY

The present summary contains a tabulation of all accepted cases through May 13, as well as five tables in which the data are organized to permit observation of characteristic patterns where they exist. At present, reports to PSU on non-vaccinated cases are not sufficiently complete to warrant a separate tabulation. The weekly data distributed by the National Office of Vital Statistics is already generally available.

During the past week an expanded list of laboratory facilities was presented. It is expected that a more definitive directory, including the area covered by each laboratory, will be available for presentation in the near future. It is also planned that general recommendations for collection, storage and shipment of specimens will be included. At present, isolation of Type 1 poliomyelitis virus from the stools of 6 Cutter associated cases has been reported. Type 3 virus has been found in the stool of a Lilly associated case. A tabulation of this information was presented in PSU Report Number 10, and in the absence of new reports is not again included.

A revision of priorities recommended for case reporting was sent as a teletype message to State Health Officers on Friday afternoon, May 13. In the near future, PSU plans to issue a definitive attachment discussing reporting procedures.

Case Incidence by State and Manufacturer

The majority of Cutter associated cases have occurred in California and Idaho, with a scattering through the rest of the country, reflecting the distribution of Cutter vaccine. Lilly associated cases have been reported mainly from the South, where most of the Lilly vaccine was distributed. Only 2 cases associated with Wyeth vaccine were reported, both from Pennsylvania, where Wyeth vaccine was used exclusively in NFIP clinics. PSU has received no reports of definite cases associated with Pittman-Moore or Parke-Davis vaccine.

Approximate Attack Rates and Lot Numbers

Table 1 provides a more detailed breakdown of data on the Cutter associated cases. The NFIP provided information on the approximate number of inoculations given in their clinics. The figures for commercial distribution are less accurate since only partial use was made of commercially distributed vaccine. There is a considerable span of attack rates from a high for NFIP clinics in Idaho, 4 to 5 per 10,000 inoculations, to a low for NFIP clinics in California (outside San Diego), Nevada and Hawaii, 0 to 1 per 10,000. Cases have been associated with many lots of Cutter vaccine. It is of interest that PSU has no accepted cases from Arizona and New Mexico, where Cutter vaccine was used in all NFIP clinics.

Cases by Date of Inoculation

In Table 2, cases have been broken down into 3 groups: NFIP clinics using Cutter vaccine, NFIP clinics using Lilly and Wyeth vaccine, and commercially distributed Cutter vaccine. It is evident that the majority of Cutter associated cases (NFIP and commercial) reported thus far received their vaccination in the first half of the two-week period, April 13 to April 28. The Lilly and Wyeth associated cases are presented for comparison.

Correlation of Site of Inoculation and First Paralysis

Table 3 shows that among most of the Cutter associated cases a correlation exists between the site of inoculation and the site of paralysis but that in only 2 of 7 paralytic Lilly associated cases was such a correlation found.

Intervals Between Inoculation and Paralysis

The interval between inoculation and first paralysis ranged between 5 and 20 days (Table 5) for Cutter associated cases with over three-quarters falling between 6 and 14 days. For comparison data from an experiment published by Dr. David Bodian is also presented. In this experiment live Mahoney virus was injected into the right calf of 32 cynomolgus monkeys and the incubation period between injection and the onset of paralysis recorded. Approximately three-quarters of the animals showed incubation periods in the range 6 to 14 days.

Comparison of Expected and Reported Cases

Through the courtesy of the NFIP, information for each state was provided, including estimated populations in 1st and 2nd grades, estimated number of children inoculated in NFIP clinics through May 7th, and manufacturer of the vaccine provided to each state. These data have been consolidated, giving an estimate of the number of inoculations given by each manufacturer (Table 5).

From data available in the Statistics Section of CDC, an estimate was made of the number of cases of poliomyelitis that might be expected to have occurred purely by chance among these groups. This estimate was based on weekly 5-year medians of reported cases of poliomyelitis for each state. Extensive studies of the age distribution of poliomyelitis in 1952 revealed that 9.7 per cent of the cases, both in the North and in the South, occurred in 7- and 8-year-old children. Therefore, as a reasonable approximation, it was assumed that 10 per cent of the 5-year median could be expected among 1st and 2nd grade children. These estimates for each state were then corrected for the per cent of the 1st and 2nd grade children inoculated prior to May 7. These estimates were consolidated and are shown in Table 5 as "expected cases." They may be compared with the "reported cases" occurring among 6, 7 and 8-year olds, and accepted by PSU.

For the period April 17 through May 7, only 3 cases were expected among 308,748 Cutter vaccinated children, whereas, 28 have been reported. During the same period a total of 12 cases were expected among 2,513,962 children inoculated with Lilly vaccine and 12 have been reported. In the weeks ending May 7 and May 14, one or less cases were expected among 775,920 children receiving Wyeth vaccine, and one case has been reported for each of these weeks. For the areas in which Pittman-Moore and Parke-Davis vaccine was distributed, the expected number of cases is one or less per week, since these vaccines were distributed for the most part in central and northern states where the expectancy of polio is relatively low at this time of year.

(This Summary Report has been prepared by Dr. Neal Nathanson, Dr. Alexander D. Langmuir, and Mr. Earl Diamond. Special assistance in the calculations in Table 5 was provided by Dr. R. E. Serfling, Mrs. Ida Sherman, Mr. Jack Karush, and Dr. Jack Hall)

Table 1

Cases and Approximate Attack Rates
Among Certain Groups Receiving Cutter Vaccine

(PSU Accepted Cases through May 13, 1955)

Distribution Outlet	Estimated Inoculations*	Accepted Cases	Approximate rates per 10,000 inoculations	Lot Numbers	Number of Cases
<u>NFIP CLINICS</u>					
San Diego	30,000	4	1-2	?E6038) ?E5970) ?E5928)	4
Idaho	33,000	15	4-5	E6058 ?E6039) ?E5058)	6 9
California (except San Diego), Nevada and Hawaii	140,000	9	0-1	E5972 E5928 E6038 E6045 E6039 ?	2 2 2 1 1 1
<u>COMMERCIAL DISTRIBUTION</u>					
	<u>Amount Distributed**</u>				
California	110,000	15	1-2	E6045 E5971 E5972 ?E6045) ?E5974)	6 6 2 1 1
United States (except California)	60,000	16	2-4	E5972 E5973 E6044 E6045 ? ?E6039) ?E6058)	7 1 4 1 2 1 1

* Numbers of estimated inoculations in NFIP Clinics through 4/28. Information provided by Dr. G. Foard McGinnes and Dr. Thomas D. Dublin who consolidated reports from States.

** Approximate figures not corrected for the amounts recovered.

Table 3

Cases by Site of Inoculation
 Site of First Paralysis, and Manufacturer

(PSU Accepted Cases through May 13, 1955)

Site of Inoculation	Site of First Paralysis	Manufacturer		
		Cutter	Lilly	Wyeth
Left arm	Left arm	29	2	1
Right arm	Right arm	3		
Left leg	Left leg	1		
Right leg	Right leg	7		
Arm	Other arm	1		
Arm	Leg	4	4	1
Arm	Bulbar	2	1	
Non-paralytic		3	5	
Data incomplete		9		
		<u>59</u>	<u>12</u>	<u>2</u>

Table 4

Cases by Distribution Outlet and
Interval between Inoculation and Onset of Paralysis

(PSU Accepted Cases through May 13, 1955)

Interval Inoculation to Onset of Paralysis	Cutter		Wyeth	Lilly	Monkey Data (Bodian)*
	NFIP Clinics	Commercial	NFIP Clinics	NFIP Clinics	
5 days		2			
6 "	2	1		1	2
7 "	3	2	1	1	1
8 "	7	1		1	8
9 "	1	6		3	
10 "	2	4	1		4
11 "	1	1			2
12 "		4			1
13 "		2			6
14 "	2	3		1	2
15 "	1				
16 "	1	1			1
17 "					1
18 "					2
19 "	1				
20 "	1				
21 "					
22 "					1
23 "					
24 "					
25 "					1
Non-paralytic	2	1		5	
Data incomplete	4	3			
Totals	28	31	2	12	32

* Data abstracted from David Bodian "Viremia in Experimental Poliomyelitis," American Journal of Hygiene, Vol. 60, page 358, November, 1954. In the experiment cited Live Mahoney virus was injected into the right calf of 32 cynomolgus macaques and the incubation period between injection and onset of paralysis recorded.

Table 5

Comparison of Expected* and Reported** Cases of
Poliomyelitis among Children Inoculated in NFIP
Clinics from April 15 to May 7, 1955

(PSU Accepted Cases through May 13, 1955)

Vaccine Mfr.***	Number Vaccinated	Cases	Week Ending					Total Apr. 17- May 7
			Apr. 23	Apr. 30	May 7	May 14	May 21	
Cutter	308,748	Exp'd.	1	0-1	1	1	2	3
		Rep'd.	5	14	9	-	-	28
Lilly	2,513,962	Exp'd.	3	4	5	6	6	12
		Rep'd.	3	6	3	-	-	12
Parke- Davis	834,148	Exp'd.	0-1	0-1	0-1	0-1	0-1	1
		Rep'd.	0	0	0	-	-	0
Pittman- Moore	410,648	Exp'd.	0-1	0-1	0-1	0-1	0-1	0-1
		Rep'd.	0	0	0	-	-	0
Wyeth	775,920	Exp'd.	0-1	0-1	0-1	0-1	0-1	0-1
		Rep'd.	0	0	1	1	-	1****

* Expected cases estimated from weekly 5-year medians of cases of poliomyelitis reported to National Office of Vital Statistics by the States.

** Reported cases for ages 6, 7, or 8 having onsets between April 17 and May 14 and accepted by PSU.

*** CUTTER vaccine was used in Idaho, Nevada, Arizona, New Mexico, and Southern California.

LILLY vaccine was used in Texas, Oklahoma, Louisiana, Arkansas, Mississippi, Alabama, Tennessee, Florida, Georgia, South Carolina, North Carolina, Virginia, West Virginia, Indiana, part of Ohio, and Colorado.

PARKE-DAVIS vaccine was used in Michigan, Illinois, Iowa, Wyoming, and Utah.

PITTMAN-MOORE vaccine was used in Kentucky, Missouri, Kansas, and Nebraska.

WYETH vaccine was used in Pennsylvania, Delaware, Maryland, District of Columbia, and part of Ohio.

**** One case with onset in the week ending May 14 is omitted since data was totaled for the period April 17 to May 7.

DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE
PUBLIC HEALTH SERVICE COMMUNICABLE DISEASE CENTER

POLIOMYELITIS SURVEILLANCE UNIT

Accepted Cases Associated with Poliomyelitis Vaccine
(Weekly Cumulative Summary)

All Cases through PSU Report No. 12

PSU CASE NO.	Residence	Init- ials	Age	Sex	Date Inoc	Date lst Symp	Date lst Para	Site Inoc	Site lst Para	Mfr	Lot No	Remarks
Cal-1	San Diego	LV	7	M	4-16	4-20	4-23	LA	LA	C	?E6038, E5970 ?E5928	
Cal-2	San Diego	JMcD	7	M	4-16	4-22	4-24	LA	LA	C	"	
Cal-3	San Diego	CE	8	F	4-16	4-25	4-27	LA	LA	C	?E6038, E5970 ?E5928	Type 1 Virus in stool 5-4 Dr. Lennette
Cal-4	Ventura	MD	1	M	4-16	4-21-	4-25	LA	LA	C	E5971	
Cal-5	Napa	GK	1	F	4-15	4-22	4-24	LA	LA	C	?E6045, ?5974	
Cal-6	Oakland	RF	4	M	4-18	4-24	4-26	LA	LA	C	E6045	Type 1 Virus in stool 5-2 Dr. Lennette
Cal-7	Oakland	JB	3	F	4-14	4-21	4-27	RL	RL	C	E6045	Type 1 virus in stool 5-8 (Dr. Lennette)
Cal-8	Los Angeles	BM	5	F	4-19	4-24	4-25	LA	LA	C	E5971	
Cal-9	Los Angeles Co.	RN	1	M	4-19	4-25	?	?	?	C	E5972	Quadriplegia
Cal-10	Los Angeles Co.	AW	6	M	4-18	4-25	4-28	LA	LA	C	?	
Cal-11	Riverside	DM	8	F	4-18	4-23	4-26	RL	RL	C	E5972	

PSU CASE NO.	Residence	Init- ials	Age	Sex	Date Inoc	Date 1st Symp	Date 1st Para
Cal-12	Stanislaw Co.	CS	2	F	4-17	4-25	4-27
Cal-14	San Diego	JMcC	6	F	4-16	4-22	None
Cal-15	Santa Barbara	AG	4	F	4-18	4-23	4-28
Cal-16	Vallejo	BG	2	F	4-21	4-27	5-3
Cal-17	Riverside	TP	6	F	4-22	4-28	?
Cal-18	San Marino	BC	12	F	4-20	4-26	4-29
Cal-19	LaCanada	CC	4	F	4-22	4-24	4-27
Cal-20	Alameda Co.	JH	24	M	4-21	4-30	5-5
Cal-21	SierraMadre	JP	1	M	4-19	4-28	5-1
Cal-22	Los Angeles Co.	LB	10	M	4-19	4-27	?
Cal-23	Los Angeles Co.	KJ	7	M	4-22	4-27	4-30
Cal-24	Riverside	DT	8	M	4-27	5-3	?
Cal-25	Tulare Co.	JS	7	F	4-26	4-26	5-3
Colo-1	Denver	SC	1	M	4-15	4-21	4-24
Conn-1	Manchester	GS	12	M	4-14	5-2	None

Site Inoc	Site 1st Para	Mfr	Lot No	Remarks
LA	?	C	E6045	
LA	None	C	E6038?, E5970?, E5928?	
RL	RL	C	E5971	
LA	LA	C	E6045	
LA	RL	C	E5928	
RL	RL	C	E5971	
?	LA	C	E5971	
RA	RA	C	E6045	
LA	Legs	C	E5972	Paraplegia
RL	Legs	C	E5971	Paraplegia
LA	LA	C	E6038	
?	RA	C	E5928	
LA	LA	C	E5972	Ill at time of inoculation
Arm	-	C	E5972	Quadriplegia
LA	None	C	E6044	Type 1 virus in stool 5-10 (Dr. Melnick)

PSU CASE NO.	Residence	Init- ials	Age	Sex	Date Inoc	Date 1st Symp
Ga-1	Columbus	KF	6	M	4-19	4-23
Ga-2	Smyrna	SS	2	M	4-20	4-29
TH-1	Hilo City	SV	7	M	4-26	5-2
Ida-1	Pocatello	SP	7	F	4-18	4-23
Ida-2	Pocatello	JS	6	M	4-20	4-26
Ida-3	Orofino	DC	8	F	4-21	4-26
Ida-4	Lewiston	BP	7	F	4-19	4-24
Ida-5	Moscow	JLK	8	F	4-19	4-25
Ida-6	Moscow	CS	7	F	4-20	4-28
Ida-7	Malad	SV	7	M	4-19	4-26
Ida-8	Preston	DC	7	M	4-19	4-26
Ida-9	Wallace	SB	5	F	4-21	4-27
Ida-10	Clearwater Co.	JG	7	M	4-21	5-1
Ida-11	Valley Co.	CH	8	F	4-19	5-2
Ida-12	Jerome Co.	UC	7	M	4-19	5-2
Ida-13	Strevell	GK	7	M	4-21	?5-4
Ida-14	Idaho Falls	DE	8	M	4-19	5-7

Date 1st Para	Site Inoc	Site 1st Para	Mfr	Lot No	Remarks
4-27	RA	Bulbar	L	E5081- 649340	Type 3 virus in stool 5-11 (Montgomery Lab)
5-2	LA	LA	C	?	
5-4	LA	LA	C	E6038	Bulbar, died 5-5
4-24	LA	LA	C	E6039? E6058?	Died 4-27, fulminating bulbar
4-27	LA	LA	C	"	
4-27	RA	RA	C	E6058	
4-27	LA	LA	C	E6058	
4-27	LA	LA	C	E6058	Bulbar, died 5-1
4-29	LA	LA	C	E6058	
4-27	RA	RA	C	E6039?,E6058?	
4-29	LA	LA	C	E6058	
5-2	LA	LA	C	E6039?,E6058?	
5-5	LA	LA	C	" "	
5-8	LA	LA	C	?	
None	LA	None	C	E6039?,E6058?	Non-paralytic
?5-5	LA	LA	C	" "	
5-9	LA	Bulbar	C	" "	Fulminating bulbar, Died 5-10

PSU CASE NO.	Residence	Init- ials	Age	Sex	Date Inoc	Date 1st Symp	Date 1st Para
Ida-15	Driggs	AD	6	F	4-25	?	?
Ida-16	Lewiston	JG	7	M	4-21	5-1	5-6
Ill-1	Chicago	EK	1	M	4-16	4-21	4-25
Ind-1	N.Vernon	WC	7	M	4-20	4-27	4-29
La-1	Winnsboro	?B	6	M	4-19	4-19	4-28
La-2	Monroe	?S	6	F	4-21	4-22	None
La-3	New Orleans	ED	2	M	4-26	5-1	5-3
Miss-1	Sunflower Co.	EA	6	F	4-18	4-24	4-24
Mo-1	St. Louis	ES	4	M	4-14 4-21	4-26	4-26
Nev-1	Ely	MS	2	M	4-17	4-28	?
Nev-2	Ely	JD	8	M	4-17	4-30	?
Nev-3	Las Vegas	MB	7	F	4-21	5-2	5-7
NY-1	Tarrytown	TG	5	F	4-16	5-1	5-2
Ohio-1	Cincinnati	TLK	1	M	4-17	4-27	4-27
Ore-1	Portland	KK	4	M	4-20	4-27	4-30
Ore-2	Portland	SJ	11	F	4-15	4-29	4-29

Site Inoc	Site 1st Para	Mfr	Lot No	Remarks
LA	LA	C	E6058	
LA	LA	C	E6039?, E6058?	
Leg	-	C	E6044	Paraplegia Type 1 virus in stool 5-3 (Dr. Shaughnessy)
LA	LA	L	8123-649335	
LA	Legs	L	5081	
Arm	None	L	5081	
LA	RA	C	E5973	Bulbar, died 5-4, ?Type 1 virus in stool 5-7, Dr. Fox.
RA	RL	L	5080-649339	Progressed to weakness of both legs and trunk; is recovering rapidly.
RA		C	?	
RA	RA	?	?	Received 2 injections.
RL	RL	C	E6045	
LL	?	C	E6045	Paralysis LL, LA.
LA?	Bulbar	C	E6039	
LA	LL	C	E6044	Slight weakness, LL only
?RL	RL	C	E6044	
LA	LA	C	E5972	
LA	Legs	C	E5972	

PSU CASE NO.	Residence	Init- ials	Age	Sex	Date Inoc	Date 1st Symp
Ore-3	Portland	EH	4	F	4-20	4-29
Pa-1	Edinboro	JSJ	7	M	4-26	5-1
Pa-2	Delaware Co.	CS	7	F	4-29	5-8
Tex-1	Houston	HH	7	M	4-19	4-27
Tex-2	Houston	EB	1	F	4-19	4-26
Tex-3	Houston	TP	9	M	4-19	4-27
Tex-4	Yoakum	GS	8	M	4-21	4-27
Tex-5	Tarrant	PGH	7	M	4-21	5-4
Va-1	Pulaski Co.	AT	7	F	4-27	5-6
Wash-1	Wiley City	VB	4	F	4-18	4-25
WVA-1	Princeton	ES	7	M	4-24	4-29
WVa-2	Mabscott	TAC	6	M	4-21	5-4
Wyo-1	Casper	CL	4	F	4-18	4-24
Wyo-2	Casper	CL	4	F	4-19	4-25

Date 1st Para	Site Inoc	Site 1st Para	Mfr	Lot No	Remarks
5-3	LA	LA	C	E5972	
5-3	LA	Legs	W	23710	
5-9	LA	LA	W	23616	Quadriplegia
4-28	LA	LA	L	7078-649343	
5-3	LL	Legs	C	E6045	
None	LA	None	L	7078-649343	
None	?	None	L	7080-649342	
None	LA	None	L	7078-649343	Non-paralytic
None	LA	None	L	7081-649343	Non-paralytic
4-27	?	LA	C	E5972	
5-1	LA	LL	L	8122-649334	
5-5	LA	Legs	L	8122-649334	
4-25	LA	LA	C	E5972	
5-1	LA	LA	C	E5972	

